INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.
Immunotherapy
; 10(14): 1229-1239, 2018 10.
Article
en En
| MEDLINE
| ID: mdl-30326787
ABSTRACT
AIM:
Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population.METHODS:
INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016-2017.RESULTS:
Of 300 patients, 79 received flu vaccine. The incidence of influenza syndrome was 24.1% among vaccinated, versus 11.8% of controls; odds ratio 2.4; 95% CI 1.23-4.59; p = 0.009. The clinical ineffectiveness of vaccine was more pronounced among elderly 37.8% among vaccinated patients, versus 6.1% of unvaccinated, odds ratio 9.28; 95% CI 2.77-31.14; p < 0.0001.CONCLUSION:
Although influenza vaccine may be clinically ineffective in advanced cancer patients receiving CKI, it seems not to negatively impact the efficacy of anticancer therapy.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Virus de la Influenza A
/
Vacunas contra la Influenza
/
Gripe Humana
/
Inmunoterapia
/
Anticuerpos Monoclonales
/
Neoplasias
Tipo de estudio:
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
País/Región como asunto:
Europa
Idioma:
En
Revista:
Immunotherapy
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Año:
2018
Tipo del documento:
Article